Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

101. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update Full Text available with Trip Pro

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies

2017 EvidenceUpdates

102. User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine Full Text available with Trip Pro

User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine Ukraine has successfully implemented e-TB Manager nationwide as its mandatory national tuberculosis registry after first introducing it in 2009. Our objective was to perform an end-of-programme evaluation after formal handover of the registry administration to Ukraine's Centre for Disease Control in 2015. We conducted a nationwide, cross-sectional, anonymous, 18-point user (...) received and satisfaction with the registry. Of the 5.9 million transactions over a 4-year period, nine out of 24 oblasts (regions) and Kiev city accounted for 62.5% of all transactions, and corresponded to 59% of Ukraine's tuberculosis burden. There were 437 unique active users in 486 rayons (districts) of Ukraine, demonstrating extensive reach. Our key findings complement the World Health Organization and European Respiratory Society's agenda for action on digital health to help implement the End TB

2017 ERJ open research

103. FluoroType MTB system for the detection of pulmonary tuberculosis Full Text available with Trip Pro

FluoroType MTB system for the detection of pulmonary tuberculosis FluoroType MTB is a sensitive test for TB but specificity is low compared with fully integrated molecular systems http://ow.ly/WhEO30b1luY.

2017 ERJ open research

104. Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked Full Text available with Trip Pro

Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked How to cite this article: Dayal S. Synchronous Colon Carcinoma and Tuberculosis: Coincidence or Linked. Euroasian J Hepato-Gastroenterol 2017;7(1):97-98.

2017 Euroasian journal of hepato-gastroenterology

105. Do incentives and enablers improve adherence to tuberculosis treatment?

Do incentives and enablers improve adherence to tuberculosis treatment? Do incentives and enablers improve adherence to tuberculosis treatment? - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Do incentives and enablers improve adherence to tuberculosis treatment? Fact sheet Have you (...) found an error? Key message What does the research show? The diagnosis and treatment of people with tuberculosis is critical for curing the disease, controlling infection and minimising drug resistance. The aim of this Cochrane Review was to find out if people were more likely to return for diagnosis appointments and follow their treatment when receiving material incentives and enablers. Cochrane authors collected and analysed all relevant research studies to answer this question. The Cochrane

2017 Norwegian Institute of Public Health

106. Renal Transplant–Associated Thyroid Tuberculosis Full Text available with Trip Pro

Renal Transplant–Associated Thyroid Tuberculosis Tuberculosis is common among solid-organ transplant recipients, including renal transplants. Tuberculosis of the thyroid gland is a rare diagnosis. We report on a renal transplant recipient with subacute fever associated with a neck mass diagnosed as thyroid tuberculosis. No prior publication has reported a case of posttransplant thyroid tuberculosis. This is an important diagnostic consideration, in addition to malignant transformation

2017 Journal of the Endocrine Society

107. Delamanid (Deltyba) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring

Delamanid (Deltyba) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring Prescrire IN ENGLISH - Spotlight ''Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring'', 1 April 2017 {1} {1} {1} | | > > > Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent (...) :  |   |   |   |   |   |   |   |   |  Spotlight Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring FEATURED REVIEW Despite delamanid's rather shaky evaluation, the available data suggest that this antibiotic should be offered to patients with multidrug-resistant tuberculosis. The noteworthy impact of delamanid on the QT interval warrants electrocardiographic

2017 Prescrire

108. The mask of acute bacterial pneumonia may disguise the face of tuberculosis Full Text available with Trip Pro

The mask of acute bacterial pneumonia may disguise the face of tuberculosis Pulmonary tuberculosis (TB) can present as acute pneumonia. Differentiation of tuberculous from non-tuberculous community-acquired pneumonia (CAP) is an important challenge in endemic areas. The purpose of this study was the comparison between characteristics of tuberculous and non-tuberculous CAP patients.In this prospective and observational study, all adult patients (aged ≥16 years) who were admitted to Imam Reza

2017 Electronic physician

109. India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality Full Text available with Trip Pro

India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality 28589035 2018 11 13 2059-7908 2 2 2016 BMJ global health BMJ Glob Health India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. e000326 10.1136/bmjgh-2017-000326 Pai Madhukar M McGill Global Health Programs & McGill International TB Centre, McGill University, Montreal, Canada. Manipal McGill Centre for Infectious Diseases, Manipal University, Manipal, India. Bhaumik Soumyadeep S BMJ

2017 BMJ global health

110. The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition Full Text available with Trip Pro

The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition Mycobacterium tuberculosis is a facultative anaerobe and its characteristic pathological hallmark, the granuloma, exhibits hypoxia in humans and in most experimental models. Thus the host and bacillary adaptation to hypoxia is of central importance in understanding pathogenesis and thereby to derive new drug treatments and vaccines.Copyright © 2016 The Author(s). Published

2017 Microbes and infection

111. Fumarase deficiency causes protein and metabolite succination and intoxicates Mycobacterium tuberculosis Full Text available with Trip Pro

Fumarase deficiency causes protein and metabolite succination and intoxicates Mycobacterium tuberculosis Enzymes of central carbon metabolism are essential mediators of Mycobacterium tuberculosis (Mtb) physiology and pathogenicity, but are often perceived to lack sufficient species selectivity to be pursued as potential drug targets. Fumarase (Fum) is an enzyme of the canonical tricarboxylic acid cycle and is dispensable in many organisms. Transposon mutagenesis studies in Mtb, however

2017 Cell chemical biology

112. Tuberculosis. (Abstract)

Tuberculosis. This issue provides a clinical overview of tuberculosis, focusing on screening, prevention, diagnosis, and treatment. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance

2017 Annals of Internal Medicine

113. Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis

Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis Baxter S, Goyder E, Chambers D, Johnson M, Preston L & Booth A. Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Baxter S, Goyder E, Chambers D, Johnson M, Preston L & Booth A.. Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis. Health Services and Delivery Research 2017; 5(1) Authors' objectives The tracing and screening of people who have had contact with an active case of tuberculosis (TB

2017 Health Technology Assessment (HTA) Database.

114. Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data Full Text available with Trip Pro

Multiple large clusters of tuberculosis in London: a cross-sectional analysis of molecular and spatial data Large outbreaks of tuberculosis (TB) represent a particular threat to disease control because they reflect multiple instances of active transmission. The extent to which long chains of transmission contribute to high TB incidence in London is unknown. We aimed to estimate the contribution of large clusters to the burden of TB in London and identify risk factors. We identified TB patients

2017 ERJ open research

115. Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance. Full Text available with Trip Pro

Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance. In this report we assess who pays for cooperation in global health through an analysis of the financial flows of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, TB and Malaria, and Gavi, the Vaccine Alliance. The past few decades have seen the consolidation of influence in the disproportionate roles the USA

2017 Lancet

116. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. Full Text available with Trip Pro

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide. A widespread epidemic of extensively drug-resistant (XDR) tuberculosis is occurring in South Africa, where cases have increased substantially since 2002. The factors driving this rapid increase have not been fully elucidated, but such knowledge is needed to guide public health (...) interventions.We conducted a prospective study involving 404 participants in KwaZulu-Natal Province, South Africa, with a diagnosis of XDR tuberculosis between 2011 and 2014. Interviews and medical-record reviews were used to elicit information on the participants' history of tuberculosis and HIV infection, hospitalizations, and social networks. Mycobacterium tuberculosis isolates underwent insertion sequence (IS)6110 restriction-fragment-length polymorphism analysis, targeted gene sequencing, and whole-genome

2017 NEJM

117. The impact of ISGylation during Mycobacterium tuberculosis infection in mice Full Text available with Trip Pro

The impact of ISGylation during Mycobacterium tuberculosis infection in mice Mycobacterium tuberculosis infection results in 1.5 million deaths annually. Type I interferon (IFN) signaling through its receptor IFNAR correlates with increased severity of disease, although how this increases susceptibility to M. tuberculosis remains uncertain. ISG15 is one of the most highly induced interferon stimulated genes (ISGs) during M. tuberculosis infection. ISG15 functions by conjugation to target (...) proteins (ISGylation), by noncovalent association with intracellular proteins, and by release from the cell. Recent studies indicated that ISG15 can function via conjugation-independent mechanisms to suppress the type I IFN response. These data raised the question of whether ISG15 may have diverse and sometimes opposing functions during M. tuberculosis infection. To address this, we analyzed ISGylation during M. tuberculosis infection and show that ISGylated proteins accumulate following infection

2017 Microbes and infection

118. Choroidal neovascularization secondary to tuberculosis: Presentation and management Full Text available with Trip Pro

Choroidal neovascularization secondary to tuberculosis: Presentation and management While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management.We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had (...) signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all

2017 American journal of ophthalmology case reports

119. Determining clinical decision thresholds for HIV-positive patients suspected of having tuberculosis

Determining clinical decision thresholds for HIV-positive patients suspected of having tuberculosis Determining clinical decision thresholds for HIV-positive patients suspected of having tuberculosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Determining clinical decision thresholds for HIV-positive patients suspected of having tuberculosis Article Text Original EBM Research Determining clinical decision thresholds for HIV

2017 Evidence-Based Medicine

120. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis

Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis Sign in JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse My Account Statistics Related Links Sign in to IRIS E-Mail Address: Password: Sign in Register new user Register an account to subscribe to collections for email updates, and submit new items to IRIS. Sign in

2017 WHO